Jang Se-Eun, Jeong Jin-Ju, Hyam Supriya R, Han Myung Joo, Kim Dong-Hyun
Department of Life and Nanopharmaceutical Sciences, ‡Department of Food and Nutrition, and §Department of Pharmacy, Kyung Hee University , Seoul 130-701, Korea.
J Agric Food Chem. 2014 Oct 8;62(40):9711-21. doi: 10.1021/jf501487v. Epub 2014 Sep 23.
Ursolic acid, which was isolated from an ethanol extract of Cornus officinalis seed, potently inhibited nuclear factor κ light-chain enhancer of activated B cells (NF-κB) activation in lipopolysaccharide (LPS)-stimulated peritoneal macrophages. Therefore, we investigated the anti-inflammatory mechanism of ursolic acid in LPS-stimulated macrophages and colitic mice. Ursolic acid inhibited phosphorylation of interleukin 1 receptor-associated kinase (IRAK)1, TAK1, inhibitor of nuclear factor κB kinase subunit β (IKKβ), and IκBα as well as activation of NF-κB and MAPKs in LPS-stimulated macrophages. Ursolic acid suppressed LPS-stimulated interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, cyclooxygenase (COX)-2, and inducible NO synthetase (iNOS) expression as well as PGE2 and NO levels. Ursolic acid not only inhibited the Alexa Fluor 488-conjugated LPS-mediated shift of macrophages but also reduced the intensity of fluorescent LPS bound to the macrophages transiently transfected with or without MyD88 siRNA. However, ursolic acid did not suppress NF-κB activation in peptidoglycan-stimulated macrophages. Oral administration of ursolic acid significantly inhibited 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon shortening and myeloperoxidase (MPO) activity in mice. Ursolic acid also suppressed TNBS-induced COX-2 and iNOS expression as well as NF-κB activation in colon tissues. Ursolic acid (20 mg/kg) also inhibited TNBS-induced IL-1β, IL-6, TNF-α by 93, 86, and 85%, respectively (p < 0.05). However, ursolic acid reversed TNBS-mediated downregulation of IL-10 expression to 79% of the normal control group (p < 0.05). On the basis of these findings, ursolic acid may ameliorate colitis by regulating NF-κB and MAPK signaling pathways via the inhibition of LPS binding to TLR4 on immune cells.
熊果酸是从山茱萸种子乙醇提取物中分离得到的,它能有效抑制脂多糖(LPS)刺激的腹腔巨噬细胞中活化B细胞核因子κ轻链增强子(NF-κB)的激活。因此,我们研究了熊果酸在LPS刺激的巨噬细胞和结肠炎小鼠中的抗炎机制。熊果酸抑制LPS刺激的巨噬细胞中白细胞介素1受体相关激酶(IRAK)1、TAK1、核因子κB激酶亚基β(IKKβ)和IκBα的磷酸化以及NF-κB和丝裂原活化蛋白激酶(MAPKs)的激活。熊果酸抑制LPS刺激的白细胞介素(IL)-1β、IL-6、肿瘤坏死因子(TNF)-α、环氧化酶(COX)-2和诱导型一氧化氮合酶(iNOS)的表达以及前列腺素E2(PGE2)和一氧化氮(NO)水平。熊果酸不仅抑制了Alexa Fluor 488偶联的LPS介导的巨噬细胞移位,还降低了与转染或未转染MyD88小干扰RNA(siRNA)的巨噬细胞结合的荧光LPS的强度。然而,熊果酸并未抑制肽聚糖刺激的巨噬细胞中NF-κB的激活。口服熊果酸可显著抑制小鼠中2,4,6-三硝基苯磺酸(TNBS)诱导的结肠缩短和髓过氧化物酶(MPO)活性。熊果酸还抑制TNBS诱导的结肠组织中COX-2和iNOS的表达以及NF-κB的激活。熊果酸(20mg/kg)还分别抑制TNBS诱导的IL-1β、IL-6、TNF-α达93%、86%和85%(p<0.05)。然而,熊果酸使TNBS介导的IL-10表达下调逆转至正常对照组的79%(p<0.05)。基于这些发现,熊果酸可能通过抑制LPS与免疫细胞上Toll样受体4(TLR4)的结合来调节NF-κB和MAPK信号通路,从而改善结肠炎。